TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp‐ and BCRP‐mediated efflux
暂无分享,去创建一个
D. Murry | Sohyun Bae | G. An | Guohua An | Daryl J Murry | Ronilda D'Cunha | SoHyun Bae | Ronilda D’Cunha | Daryl J. Murry | Ronilda R. D’Cunha
[1] Liwu Fu,et al. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. , 2013, Cancer letters.
[2] Sagar Agarwal,et al. Brain Distribution and Bioavailability of Elacridar after Different Routes of Administration in the Mouse , 2012, Drug Metabolism and Disposition.
[3] S. Giordano,et al. ReviewMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapy , 2015 .
[4] Fabian Müller,et al. Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects , 2013, Pharmacological Reviews.
[5] P. Houghton,et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Stewart,et al. Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation , 2010, Clinical Cancer Research.
[7] T. Fojo,et al. ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition , 2014 .
[8] Zhe-Sheng Chen,et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.
[9] T. Merchant,et al. Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma , 2009, Clinical Cancer Research.
[10] K. Shannon. Resistance in the land of molecular cancer therapeutics. , 2002, Cancer cell.
[11] Jos H. Beijnen,et al. Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.
[12] Pramodita Sharma. 2012 , 2013, Les 25 ans de l’OMC: Une rétrospective en photos.
[13] J. Melo,et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.
[14] S. Ambudkar,et al. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[15] L. Fu,et al. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. , 2010, Current drug metabolism.
[16] B. Qin,et al. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. , 2012, International journal of pharmaceutics.
[17] Wolfgang Löscher,et al. Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.
[18] C. Waters,et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. , 2010, Cancer research.
[19] S. Baker,et al. Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide , 2013, Clinical Cancer Research.
[20] J. Blay,et al. A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.
[21] M. Harrison. Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib? , 2011, Clinical Medicine Insights. Oncology.
[22] J. Markowitz,et al. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. , 2014, Journal of pharmaceutical sciences.
[23] Michael O'Connor,et al. A novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transporters , 2014, Pharmacology research & perspectives.
[24] Ian F Tannock,et al. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors , 2009, BMC Cancer.
[25] L. Fu,et al. Mechanisms of acquired resistance to tyrosine kinase inhibitors , 2011 .
[26] M. Rudek,et al. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib , 2015, Cancer Chemotherapy and Pharmacology.
[27] P. Lakshmi,et al. Overview of P-glycoprotein inhibitors: a rational outlook , 2012 .
[28] A. Mitra,et al. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors , 2014, Drug metabolism and drug interactions.
[29] Caroline A. Lee,et al. In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions , 2013, Drug Metabolism and Disposition.
[30] A. Ardizzoni,et al. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines , 2015, PloS one.
[31] M. Pirmohamed,et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.
[32] J. Markowitz,et al. ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors , 2014, Pharmaceutical Research.
[33] Peter Lloyd,et al. Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.
[34] K. Giacomini,et al. Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins , 2011, Molecular Cancer Therapeutics.
[35] P. Manley,et al. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. , 2007, Blood.
[36] G. Szakács,et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.
[37] Balázs Sarkadi,et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). , 2008, Drug discovery today.
[38] D. Murry,et al. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans , 2015, The AAPS Journal.
[39] U. Fuhr,et al. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.
[40] S. Bates,et al. The challenge of exploiting ABCG2 in the clinic. , 2011, Current pharmaceutical biotechnology.
[41] M. He,et al. Reversing multidrug resistance by tyrosine kinase inhibitors , 2012, Chinese journal of cancer.
[42] R. Perez-soler,et al. Tyrosine kinase inhibitors: A clinical perspective , 2002, Current oncology reports.
[43] P. le Coutre,et al. Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer , 2015, Biomarker insights.
[44] Brett Fleisher,et al. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. , 2015, Journal of pharmaceutical sciences.
[45] Y. Sugimoto,et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.
[46] T. Friedberg,et al. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. , 2002, Biochemical pharmacology.